A Korean business publication reported Wednesday that Samsung is in the process of making a buyout bid for Biogen, raising equal parts skepticism and anticipation around a possible deal. The report…
Five years after little Leo Pharma put up its dukes and $115 million in cash to acquire and advance tralokinumab for atopic dermatitis, the Danish biotech has crossed the regulatory finish lines with…
Close to 6 months after it initially posted its S-1 in what was still a thriving biotech IPO market, Castle Creek Biosciences has now yanked the offering as new deals fade against the background of a…
Ionis’ heart disease drug has had many names over the years, and, now, it has yet another plus a Big Pharma partner in AstraZeneca and billions in potential biobucks down the line. Eplontersen is the…
DNA abnormalities can disrupt normal cellular processes and give rise to cancer. Now, scientists at the La Jolla Institute for Immunology hope their findings on the role of two unusual DNA structures…
Typically used in preclinical research to gauge the brain’s response to potential new drugs, Emulate’s Brain-Chip packs five types of neural and vascular cells into microfluidic channels about the…
Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing advantage.…
The biggest biotech IPO of 2021 belongs to a cell therapy developer that has yet to reach the clinic. Cell therapy and artificial intelligence were hot categories of newly public companies, but even…
Mike Linnert and Ryan Younger Michael Linnert, Founder and CEO of Actium Health is on a mission to help healthcare organizations – from practice groups to health systems – leverage their audience data to improve patient engagement, health outcomes and exceed business goals. At Actium, he’s guiding those organizations successfully through the consumerization journey to …
Mike Linnert and Ryan Younger, Author at MedCity News Read More »
The FDA has accepted Amylyx Pharmaceuticals’ submission for amyotrophic lateral sclerosis drug AMX0035 and it expects to issue a regulatory decision by late June. A lot will happen before then. Amylyx…
